- Home
- OGG vs NGNE Comparison
OGG vs NGNE Comparison
Compare OGG & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OGG | NGNE |
|---|---|---|
| Founded | N/A | 2003 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 691.2M | 744.9M |
| IPO Year | 2022 | 2014 |
Fundamental Metrics
Financial Performance| Metric | OGG | NGNE |
|---|---|---|
| Price | $2.70 | $35.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $63.57 |
| AVG Volume (30 Days) | ★ 1.2M | 231.8K |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.22 | $15.93 |
| 52 Week High | $2.53 | $43.66 |
Technical Indicators
Market Signals| Indicator | OGG | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 92.23 | 54.01 |
| Support Level | $2.22 | $19.06 |
| Resistance Level | N/A | $43.66 |
| Average True Range (ATR) | 0.11 | 1.95 |
| MACD | 0.03 | -0.43 |
| Stochastic Oscillator | 87.16 | 57.51 |
Price Performance
Historical ComparisonAbout NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.